“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by CBO without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.
You may also be interested in...
Obesity Drugs: Jury's Still Out On Potential US Health Care Savings, CBO Says
The Congressional Budget Office’s perception of the limits of current data on the broader health benefits of anti-obesity medications highlights the challenges facing legislation enabling Medicare coverage for the drugs.
Medicare Coverage For Lilly’s Tirzepatide Could Be ‘Unlocked’ With Heart Failure, Apnea Claims
The problem that obesity drugs are not covered by Medicare Part D might be alleviated if Lilly’s weight loss candidate is also cleared for indications that are reimbursed. Policy and treatment experts discuss the importance of proving obesity drugs can lower federal government health care spending during a recent discussion convened by the Institute for Clinical and Economic Review.
Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.